Strategic Science & Technologies LLC
pharmaceutical treatment for Female Sexual Arousal Disorder
- Sector
- Biotech
- Headquarters
- CAMBRIDGE, MA
- Latest Form D
- $5.1M, Jan 2014
- Total capital
- $5.1M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $5.1M
- 1 Form D · last Jan 2014
- 154 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 11
- 13 pending · first 2015
- Rank in peer group#156 of 1449
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 1st filing$5.1M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 1449 peers
Line = medianBiotech · Molecule
- Granted patents#156 · top 11%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Eric FosselResearcherExecutive Officer, DirectorLinked by 11 patents
- Daniel PetersDirectorNamed in SEC Form D filings
- John GillisDirectorNamed in SEC Form D filings
- Michael AustinExecutive Officer, DirectorNamed in SEC Form D filings
What it has protected
USPTO · 11 granted of 24- PendingTreatment Of Erectile Dysfunction And Other IndicationsUSPTOApplication 18906380
- GrantedTreatment Of Erectile Dysfunction And Other IndicationsUSPTOUS 12,138,268
- GrantedTreatment Of Erectile Dysfunction And Other IndicationsUSPTOUS 11,684,624
Show all 24 patent records
- Treatment Of Erectile Dysfunction And Other IndicationsJul 31, 2025 · Application 18906380Pending
- Treatment Of Erectile Dysfunction And Other IndicationsNov 12, 2024 · US 12,138,268Granted
- Treatment Of Erectile Dysfunction And Other IndicationsJun 27, 2023 · US 11,684,624Granted
- Treatment Of Erectile Dysfunction And Other IndicationsJun 16, 2020 · US 10,682,357Granted
- Treatment Of Erectile Dysfunction And Other IndicationsJan 8, 2019 · US 10,172,865Granted
- Treatment Of Erectile Dysfunction And Other IndicationsDec 5, 2017 · US 9,833,456Granted
- Treatment Of Erectile Dysfunction And Other IndicationsAug 22, 2017 · US 9,737,543Granted
- Treatment Of Erectile Dysfunction And Other IndicationsJun 13, 2017 · US 9,675,619Granted
- Treatment Of Erectile Dysfunction And Other IndicationsNov 22, 2016 · US 9,498,482Granted
- Treatment Of Erectile Dysfunction And Other IndicationsNov 15, 2016 · US 9,492,458Granted
- Delivery Of Ibuprofen And Other CompoundsOct 4, 2016 · US 9,457,092Granted
- Delivery Of Ibuprofen And Other CompoundsMay 19, 2016 · Application 15003048Pending
- Transdermal Formulations Of FluticasoneMar 24, 2016 · Application 14773586Pending
- Transdermal Delivery Of Sildenafil And Other Phosphodiesterase Type 5 InhibitorsMar 10, 2016 · Application 14773593Pending
- Transdermal Delivery Of Beneficial Substances Effected By A Hostile Biophysical EnvironmentDec 3, 2015 · Application 14682211Pending
- Delivery Of Ibuprofen And Other CompoundsOct 13, 2015 · US 9,155,701Granted
- Delivery Of Naproxen And Other CompoundsSep 17, 2015 · Application 14724915Pending
- Transdermal Delivery Of Beneficial Substances Effected By A Hostile Biophysical EnvironmentMar 19, 2015 · Application 14551153Pending
- Transdermal Delivery Of Beneficial Substances Effected By A Hostile Biophysical EnvironmentJan 8, 2015 · Application 14492394Pending
- Methods And Systems For Treatment Of Migraines And Other IndicationsJan 8, 2015 · Application 14497910Pending
- Techniques And Systems For Transdermal Delivery Involving Treatment Of Psoraisis, Skin Cancer, And Other IndicationsApplication 62100523Pending
- Transdermail Formulations Of FluticasoneApplication PCTUS2014027157Pending
- Transdermal Delivery Of Sildenafil And Other Phosphodiesterase Type 5 InhibitorsApplication PCTUS2014027277Pending
- Techniques And Systems For Transdermal Delivery Involving Treatment Of Psoraisis, Skin Cancer, And Other IndicationsApplication PCTUS2016012504Pending
Related companies, and why
- Lumena Pharmaceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Mosaic Biosciences, Inc.Similar federal contract value in Biotech · null in contracts
- Resolve Therapeutics LLCSimilar federal contract value in Biotech · null in contracts
- Stem Cell Reserve, LPSimilar federal contract value in Biotech · null in contracts
- Disket IncSimilar federal contract value in Biotech · null in contracts
- Celltex Therapeutics CorpSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .